Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Chromatin/Epigenetics >> JAK

JAK

Janus kinases (JAKs), belonging to a distinct family of tyrosine kinases, are non-receptor tyrosine kinases that transduce signals of cytokine receptors via diverse signal transduction pathways. Mammalian JAK family consists of four structurally similar members, JAK1, JAK2, JAK3 and Tyrosine kinase 2 (TYK2), which are characterized by containing seven JAK homology (JH) domains. The presence of JH1 and JH2 domains is the most intriguing feature of JAK proteins. JH1 domain is the main catalytic domain; while JH2 is usually considered as a catalytically inactive pseudokinase domain. However, results of recent studies have shown that JH2 acts as a dual-specificity protein kinase to phosphorylate two regulatory sites (Ser523 and Tyr570) in JAK2.

Products for  JAK

  1. Cat.No. Product Name Information
  2. GC72769 (1R)-AZD-1480 (1R)-AZD-1480 is the (1R) chiral isomer of AZD-1480, an ATP competitive JAK1 and JAK2 inhibitor. (1R)-AZD-1480 Chemical Structure
  3. GC62130 (2R,5S)-Ritlecitinib

    (2R,5S)-PF-06651600

     (2R,5S)-Ritlecitinib ((2R,5S)-PF-06651600) is a potent and selective JAK3 inhibitor (IC50=144.8 nM) extracted from patent US20150158864A1, example 68. (2R,5S)-Ritlecitinib Chemical Structure
  4. GC34971 (3R,4S)-Tofacitinib (3R,4S)-Tofacitinib is an less active enantiomer of Tofacitinib. (3R,4S)-Tofacitinib Chemical Structure
  5. GC34972 (3S,4R)-Tofacitinib (3S,4R)-Tofacitinib is an less active enantiomer of Tofacitinib. (3S,4R)-Tofacitinib Chemical Structure
  6. GC34973 (3S,4S)-Tofacitinib (3S,4S)-Tofacitinib is the less active S-enantiomer of Tofacitinib. (3S,4S)-Tofacitinib Chemical Structure
  7. GC61807 (E/Z)-AG490 (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3. (E/Z)-AG490 Chemical Structure
  8. GC63864 (E/Z)-Zotiraciclib hydrochloride

    (E/Z)-TG02 hydrochloride; (E/Z)-SB1317 hydrochloride

     (E/Z)-Zotiraciclib ((E/Z)-TG02) hydrochloride is a potent CDK2, JAK2, and FLT3 inhibitor. (E/Z)-Zotiraciclib hydrochloride Chemical Structure
  9. GC17055 1,2,3,4,5,6-Hexabromocyclohexane

    Potently and directly inhibits JAK2 tyrosine kinase autophosphorylation, specifically inhibiting ligand-dependent JAK2 activation.

     1,2,3,4,5,6-Hexabromocyclohexane Chemical Structure
  10. GC62233 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide GDC-046 is a potent, selective, and orally bioavailable TYK2 inhibitor with Kis of 4.8, 0.7, 0.7, and 0.4 nM for TYK2, JAK1, JAK2, and JAK3, respectively. 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide Chemical Structure
  11. GC46503 2-(1,8-Naphthyridin-2-yl)phenol

    2-NP

     2-(1,8-Naphthyridin-2-yl)phenol is a selective enhancer of STAT1 transcription. 2-(1,8-Naphthyridin-2-yl)phenol can enhance the ability of IFN-γ to inhibit the proliferation of human breast cancer and fibrosarcoma cells. 2-(1,8-Naphthyridin-2-yl)phenol Chemical Structure
  12. GC32023 Abrocitinib (PF-04965842)

    PF-04965842

     Abrocitinib (PF-04965842) (PF-04965842) is a potent, orally active and selective JAK1 inhibitor, with IC50s of 29 and 803 nM for JAK1 and JAK2, respectively. Abrocitinib (PF-04965842) Chemical Structure
  13. GC50003 AG 490 EGFR-kinase inhibitor. Also JAK2, JAK3 inhibitor AG 490 Chemical Structure
  14. GC10638 AT9283 A broad spectrum kinase inhibitor AT9283 Chemical Structure
  15. GC50066 Atiprimod dihydrochloride JAK2 inhibitor Atiprimod dihydrochloride Chemical Structure
  16. GN10627 Atractylenolide I Atractylenolide I Chemical Structure
  17. GC13433 AZ 960 A JAK2 inhibitor AZ 960 Chemical Structure
  18. GC12504 AZD1480 A potent JAK2 inhibitor AZD1480 Chemical Structure
  19. GC11572 Bardoxolone methyl

    Bardoxolone methyl, NSC 713200, RTA 402, TP155

     A synthetic triterpenoid with potent anticancer and antidiabetic activity Bardoxolone methyl Chemical Structure
  20. GC14844 Baricitinib (LY3009104, INCB028050)

    INCB 028050, LY3009104

     A JAK1 and JAK2 inhibitor Baricitinib (LY3009104, INCB028050) Chemical Structure
  21. GC13830 Baricitinib phosphate A JAK1 and JAK2 inhibitor Baricitinib phosphate Chemical Structure
  22. GC91506 Bayer 18 Bayer 18 is a tyrosine kinase 2 (TYK2) inhibitor (IC50 = 18.7 nM). Bayer 18 Chemical Structure
  23. GC32028 BMS-066 BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor, with IC50s of 9 nM and 72 nM, respectively. BMS-066 Chemical Structure
  24. GC12454 BMS-911543 A potent, selective JAK2 inhibitor BMS-911543 Chemical Structure
  25. GC62491 BMS-986202 BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC50 of 0.19 nM and a Ki of 0.02 nM. BMS-986202 Chemical Structure
  26. GC25168 Brepocitinib (PF-06700841)

    PF-841

     Brepocitinib (PF-06700841, PF-841) is a potent inhibitor of Tyk2 and Jak1 with IC50s of 23 nM, 17 nM, 77 nM for Tyk2, Jak1 and Jak2 respectively. It has appropriate in-family selectivity against JAK2 and JAK3. Brepocitinib (PF-06700841) Chemical Structure
  27. GC35554 Brevilin A

    6-O-Angeloylprenolin, Brevelin A

     A sesquiterpene lactone with anticancer activity Brevilin A Chemical Structure
  28. GC68819 Butyzamide

    Butyzamide is an orally effective Mpl activator, where Mpl is a receptor for thrombopoietin (TPO) involved in platelet production. Butyzamide increases the phosphorylation levels of JAK2, STAT3, STAT5 and MAPK. In mouse xenograft experiments, Butyzamide increases human platelet levels.

     Butyzamide Chemical Structure
  29. GC12083 CEP-33779 A potent, orally available inhibitor of JAK2 CEP-33779 Chemical Structure
  30. GC11209 Cerdulatinib (PRT062070)

    PRT062070, PRT2070

     Cerdulatinib (PRT062070) (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively. Cerdulatinib (PRT062070) Chemical Structure
  31. GC11652 CHZ868 Type II JAK2 inhibitor CHZ868 Chemical Structure
  32. GC62908 Coumermycin A1

    Coumermycin A1 is a JAK2 signal activator.

     Coumermycin A1 Chemical Structure
  33. GN10442 Curculigoside Curculigoside Chemical Structure
  34. GC17050 CYT387

    Momelotinib

     A potent inhibitor of JAK1 and JAK2 CYT387 Chemical Structure
  35. GC16468 CYT387 sulfate salt A potent inhibitor of JAK1 and JAK2 CYT387 sulfate salt Chemical Structure
  36. GC10770 Decernotinib(VX-509)

    Decernotinib, VRT-831509

     Decernotinib(VX-509) is a potent, orally active JAK3 inhibitor, with Kis of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively. Decernotinib(VX-509) Chemical Structure
  37. GC31660 Delgocitinib (JTE-052) Delgocitinib (JTE-052) (JTE-052) is a specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. Delgocitinib (JTE-052) Chemical Structure
  38. GC43406 Delphinidin (chloride)

    Ephdine

    Delphinidin (chloride) is an anthocyanidin, a natural plant pigment which serves as the precursor of certain anthocyanins that provide the blue-red colors of flowers, fruits, and red wine.

     Delphinidin (chloride) Chemical Structure
  39. GC71575 Deuruxolitinib Deuruxolitinib, a deuterated Ruxolitinib , modulates the activity of JAK1/JAK2. Deuruxolitinib Chemical Structure
  40. GC46148 Filgotinib-d4

    GLPG0634-d4

     An internal standard for the quantification of filgotinib Filgotinib-d4 Chemical Structure
  41. GC16875 FLLL32

    JAK2 Inhibitor X

     STAT3 inhibitor FLLL32 Chemical Structure
  42. GC19408 FM381

    FM-381 is a highly potent and JAK3-selective janus kinase (JAK) inhibitor

     FM381 Chemical Structure
  43. GC70307 Fosifidancitinib Fosifidancitinib is a potent and selective inhibitor of JAK kinases 1/3. Fosifidancitinib Chemical Structure
  44. GC62246 G5-7 G5-7, an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study. G5-7 Chemical Structure
  45. GC68378 GDC-4379 GDC-4379 Chemical Structure
  46. GN10584 Ginsenoside Rk1 Ginsenoside Rk1 Chemical Structure
  47. GC12579 GLPG0634

    GLPG0634

     GLPG0634 (GLPG0634) is a selective and orally active JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. GLPG0634 Chemical Structure
  48. GC17222 GLPG0634 analogue GLPG0634 analogue (Compoun 176) is a broad spectrum JAK inhibitor with IC50 values of <100 nM against JAK1, JAK2 and JAK3. GLPG0634 analogue Chemical Structure
  49. GC69190 GS-829845

    GS-829845 is the main active metabolite of Filgotinib. It is a JAK1 inhibitor, but its potency is about 10 times lower than that of the parent compound and it has a longer half-life.

     GS-829845 Chemical Structure
  50. GC33041 Gusacitinib (ASN-002)

    ASN-002

     Gusacitinib (ASN-002) (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. Gusacitinib (ASN-002) has anti-cancer activity in both solid and hematological tumor types. Gusacitinib (ASN-002) Chemical Structure
  51. GC73627 HDAC/JAK/BRD4-IN-1 HDAC/JAK/BRD4-IN-1(compound 25ap) is a potent HDAC/JAK/BRD4 triple inhibitor. HDAC/JAK/BRD4-IN-1 Chemical Structure
  52. GC64108 Ifidancitinib

    ATI-50002; ATI-502

     Ifidancitinib (ATI-50002) is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib Chemical Structure
  53. GC47450 IL-4 Inhibitor IL-4 Inhibitor (compound 52) is an IL-4 inhibitor, with an EC50 of 1.81 μM. IL-4 Inhibitor Chemical Structure
  54. GC32809 Ilginatinib (NS-018)

    NS-018

     Ilginatinib (NS-018) (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). Ilginatinib (NS-018) Chemical Structure
  55. GC33037 Ilginatinib hydrochloride (NS-018 hydrochloride)

    NS-018 hydrochloride

     Ilginatinib hydrochloride (NS-018 hydrochloride) (NS-018 hydrochloride) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). Ilginatinib hydrochloride (NS-018 hydrochloride) Chemical Structure
  56. GC33018 Ilginatinib maleate (NS-018 (maleate))

    NS-018 maleate

     Ilginatinib maleate (NS-018 (maleate)) (NS-018 maleate) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). Ilginatinib maleate (NS-018 (maleate)) Chemical Structure
  57. GC63309 Ilunocitinib Ilunocitinib (compound 27) is a JAK inhibitor (extracted from patent WO2009114512A1). Ilunocitinib Chemical Structure
  58. GC19204 Itacitinib

    INCB 039110

     Itacitinib is a potent and selective inhibitor of JAK1, with >20-fold selectivity for JAK1 over JAK2 and >100-fold over JAK3 and TYK2; Itacitinib is used in the research of myelofibrosis. Itacitinib Chemical Structure
  59. GC36351 Itacitinib adipate

    INCB039110 adipate

     Itacitinib adipate is an orally bioavailable and selective JAK1 inhibitor which has been tested for efficacy and safety in a phase II trial in myelofibrosis. Itacitinib adipate Chemical Structure
  60. GC63416 Itacnosertib

    TP-0184

     Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871. Itacnosertib Chemical Structure
  61. GC72815 Itacnosertib (hydrocholide)

    TP-0184 (hydrocholide

     Itacnosertib drocholide is an inhibitor of JAK2, ACVR1 (ALK2) and ALK5. Itacnosertib (hydrocholide) Chemical Structure
  62. GC62313 Izencitinib

    TD-1473; JNJ-8398

     Izencitinib (TD-1473) is an orally active, non-selective and gut-restricted JAK inhibitor. Izencitinib Chemical Structure
  63. GC70213 JAK 3i JAK3i is a highly selective JAK3 inhibitor (IC50: 0.43 nM). JAK 3i Chemical Structure
  64. GC31866 JAK inhibitor 1 JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. JAK inhibitor 1 Chemical Structure
  65. GC91148 JAK Inhibitor 31

    A JAK2 inhibitor

     JAK Inhibitor 31 Chemical Structure
  66. GC31999 JAK-IN-1 JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 Chemical Structure
  67. GC36366 JAK-IN-10 JAK-IN-10 is a JAK inhibitor. JAK-IN-10 Chemical Structure
  68. GC63448 JAK-IN-14 JAK-IN-14 is a potent and selective JAK1 inhibitor, with an IC50 of <5 μM. JAK-IN-14 Chemical Structure
  69. GC73148 JAK-IN-21 JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively. JAK-IN-21 Chemical Structure
  70. GC68000 JAK-IN-23 JAK-IN-23 Chemical Structure
  71. GC71213 JAK-IN-24 JAK-IN-24 is a JAK inhibitor, with IC50s of 0.534 and 24 nM at the presence of 4 μM or 1mM ATP, respectively. JAK-IN-24 Chemical Structure
  72. GC69306 JAK-IN-25

    JAK-IN-25 (compound 19) is an effective JAK inhibitor with IC50 values of 6 nM, 21 nM, 8 nM, and 1051 nM for TYK2, JAK1, JAK2, and JAK3 respectively. It inhibits human whole blood IL-12 (HEB IL-12) with an IC50 value of 28 nM. JAK-IN-25 has potential for use in cancer research.

     JAK-IN-25 Chemical Structure
  73. GC73475 JAK-IN-26 JAK-IN-26 (compound 2) is an orally active JAK inhibitor with good pharmacokinetic characteristics. JAK-IN-26 Chemical Structure
  74. GC65453 JAK-IN-3 JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively. JAK-IN-3 Chemical Structure
  75. GC64959 JAK/HDAC-IN-1 JAK/HDAC-IN-1 is a potent JAK2/HDAC dual inhibitor, exhibits antiproliferative and proapoptotic activities in several hematological cell lines. JAK/HDAC-IN-1 shows IC50s of 4 and 2 nM for JAK2 and HDAC, respectively. JAK/HDAC-IN-1 Chemical Structure
  76. GC73456 JAK1-IN-11 JAK1-IN-11 (compound 11) is a potent inhibitor of JAK，with IC50s of 0.02 nM (JAK1)，and 0.44 nM (JAK2)，respectively. JAK1-IN-11 Chemical Structure
  77. GC71475 JAK1-IN-13 JAK1-IN-13 (compound 36b) is an orally active, potent and highly selective inhibitor of JAK1 with an IC50 of 0.044 nM. JAK1-IN-13 Chemical Structure
  78. GC33036 JAK1-IN-3

    Golidocitinib; AZD4205

     JAK1-IN-3 (AZD4205) is a selective JAK1 inhibitor, with an IC50 of 73 nM, weakly inhibits JAK2 (IC50>14.7 μM), and shows little inhibition on JAK3 (IC50>30 μM). JAK1-IN-3 Chemical Structure
  79. GC33258 JAK1-IN-4 JAK1-IN-4 is a potent and selective JAK1 inhibitor, with IC50s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. JAK1-IN-4 inhibits STAT3 phosphorylation in NCI-H 1975 cells (IC50, 227 nM). JAK1-IN-4 Chemical Structure
  80. GC36363 JAK1-IN-7

    JAK1-IN-7

     JAK1-IN-7 (JAK1-IN-7) is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect. JAK1-IN-7 Chemical Structure
  81. GC63029 JAK1-IN-8 JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1. JAK1-IN-8 Chemical Structure
  82. GC13826 JAK2 Inhibitor V, Z3

    Z3; NSC 42834;1-Butanone, 2-methyl-1-phenyl-4-(2-pyridinyl)-2-[2-(2-pyridinyl)ethyl]-

     A selective inhibitor of the autophosphorylation of wild type and V617F mutant forms of JAK JAK2 Inhibitor V, Z3 Chemical Structure
  83. GC36364 JAK2-IN-4 JAK2-IN-4 (compound 16h) is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively. JAK2-IN-4 Chemical Structure
  84. GC65405 JAK2-IN-6 JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective JAK2 inhibitor with an IC50 of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells. JAK2-IN-6 Chemical Structure
  85. GC62500 JAK2-IN-7 JAK2-IN-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities. JAK2-IN-7 Chemical Structure
  86. GC69305 JAK2/FLT3-IN-1

    JAK2/FLT3-IN-1 is an orally effective dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3 respectively. It has anti-cancer activity.

     JAK2/FLT3-IN-1 Chemical Structure
  87. GC62665 JAK2/FLT3-IN-1 TFA JAK2/FLT3-IN-1 (TFA) is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. JAK2/FLT3-IN-1 (TFA) has anti-cancer activity. JAK2/FLT3-IN-1 TFA Chemical Structure
  88. GC36365 JAK3 covalent inhibitor-1 JAK3 covalent inhibitor-1 is a potent and selective janus kinase 3 (JAK3) covalent inhibitor with an IC50 of 11 nM and shows 246-fold selectivity vs other JAKs. JAK3 covalent inhibitor-1 Chemical Structure
  89. GC33046 JAK3-IN-1 JAK3-IN-1 is a potent, selective and orally active JAK3 inhibitor with an IC50 of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for JAK3 than JAK1 (IC50 of 896 nM) and JAK2 (IC50 of 1050 nM). JAK3-IN-1 Chemical Structure
  90. GC73600 JAK3-IN-14 JAK3-IN-14 (compound 1) is a potent JAK3 inhibitor, with IC50 values of 38 and 600 nM for JAK3 and JAK2, respectively. JAK3-IN-14 Chemical Structure
  91. GC31902 JAK3-IN-6 JAK3-IN-6 is a potent, selective irreversible Janus Associated Kinase 3 (JAK3) inhibitor, with an IC50 of 0.15 nM. JAK3-IN-6 Chemical Structure
  92. GC33382 JAK3-IN-7 JAK3-IN-7 is a potent and selective JAK3 inhibitor extracted from patent WO2011013785A1, has an IC50 of <0.01 μM. JAK3-IN-7 Chemical Structure
  93. GC14671 JANEX-1

    Janex 1

     A selective JAK3 inhibitor JANEX-1 Chemical Structure
  94. GC91059 LCC-12 (formate)

    A copper (II) chelator and derivative of metformin

     LCC-12 (formate) Chemical Structure
  95. GC71392 Lepzacitinib Lepzacitinib is a Janus kinase inhibitor targeting to JAK 1/3. Lepzacitinib Chemical Structure
  96. GC14857 LFM-A13 BTK-specific tyrosine kinase inhibitor LFM-A13 Chemical Structure
  97. GC64372 Lorpucitinib

    JNJ-64251330

     Lorpucitinib is a Gut-Restricted JAK Inhibitor for the research of Inflammatory Bowel Disease. Lorpucitinib Chemical Structure
  98. GC13848 LY2784544

    Gandotinib

     Potent inhibitor of JAK2 LY2784544 Chemical Structure
  99. GC36646 Momelotinib Mesylate

    CYT387 Mesylate

     Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3. Momelotinib Mesylate Chemical Structure
  100. GC40791 MS-1020 MS-1020 is a cell-permeable inhibitor of janus kinase 3 (JAK3), strongly inhibiting constitutive autophosphorylation of JAK3 in L540 cells when used at 30-50 μM. MS-1020 Chemical Structure
  101. GC66329 NDI-034858 NDI-034858 is a TYK2 inhibitor, target TYK2 JH2 domain with binding constant Kd of <200 pM. NDI-034858 Chemical Structure

Items 1 to 100 of 160 total

per page
  1. 1
  2. 2

Set Descending Direction